Desmeules Simon, Arcand-Bossé Jean-François, Bergeron Jean, Douville Pierre, Agharazii Mohsen
Department of Medicine, Centre Hospitalier Universitaire de Québec-Hôtel-Dieu de Québec, 11, Côte de Palais, Québec, Canada.
Am J Kidney Dis. 2005 Jun;45(6):1067-72. doi: 10.1053/j.ajkd.2005.03.002.
Guidelines for the management of dyslipidemia in patients with chronic kidney disease are based on results from the fasting lipid profile, which can be difficult to obtain from patients on an afternoon or night dialysis schedule. The present study tests the hypothesis that nonfasting non-high-density lipoprotein (HDL) cholesterol (total cholesterol-HDL cholesterol) results are similar to fasting non-HDL results as a basis for the management of dyslipidemia in hemodialysis patients.
Forty-eight long-term hemodialysis patients with a mean age of 63.6 years (42% with diabetes, 54% administered statins) participated in this study. For the lipid profile, blood samples were drawn after a 12-hour overnight fast (fasting) and again in a nonfasting state before the subsequent hemodialysis session. Data were analyzed by using paired t-test and regression analysis.
Non-HDL cholesterol values were nearly identical regardless of whether the patient was fasting (r2 = 0.995). Only 2 patients (4%) had a nonfasting triglyceride (TG) level greater than 500 mg/dL (> 5.6 mmol/L), which would have required confirmation after an overnight fast. Non-HDL values had the greatest level of correlation (absolute relative difference, 5.7%). When comparing the subgroup of patients with a TG level less than 200 mg/dL (< 2.3 mmol/L), nonfasting non-HDL cholesterol values identified 3 additional patients compared with fasting calculated low-density lipoprotein cholesterol for whom lipid-lowering therapy would have been introduced according to current guidelines.
In our study, non-HDL cholesterol levels were equivalent whether evaluated in the fasting or nonfasting state. We recommend that nonfasting non-HDL cholesterol level be used for the management of dyslipidemia in hemodialysis patients without imposing a 12-hour fast period.
慢性肾脏病患者血脂异常管理指南基于空腹血脂谱的结果制定,而对于接受下午或夜间透析治疗的患者而言,获取空腹血脂谱可能存在困难。本研究旨在验证以下假设:非空腹状态下的非高密度脂蛋白(HDL)胆固醇(总胆固醇-HDL胆固醇)结果与空腹非HDL结果相似,可作为血液透析患者血脂异常管理的依据。
48例长期血液透析患者参与本研究,平均年龄63.6岁(42%患有糖尿病,54%服用他汀类药物)。采集血脂谱时,在禁食12小时过夜后(空腹状态)抽取血样,并在随后的血液透析治疗前再次在非空腹状态下抽取血样。采用配对t检验和回归分析对数据进行分析。
无论患者是否空腹,非HDL胆固醇值几乎相同(r2 = 0.995)。只有2例患者(4%)的非空腹甘油三酯(TG)水平大于500 mg/dL(> 5.6 mmol/L),这种情况需要在过夜禁食后进行确认。非HDL值的相关性最强(绝对相对差异为5.7%)。在比较TG水平低于200 mg/dL(< 2.3 mmol/L)的患者亚组时,与根据当前指南应启动降脂治疗的空腹计算低密度脂蛋白胆固醇相比,非空腹非HDL胆固醇值又额外识别出3例患者。
在我们的研究中,无论在空腹还是非空腹状态下评估,非HDL胆固醇水平都是相当的。我们建议在不要求12小时禁食的情况下,将非空腹非HDL胆固醇水平用于血液透析患者血脂异常的管理。